A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
Background: Carfilzomib is a second-generation proteasome inhibitor (PI) used for combination therapy with dexamethasone and/or lenalidomide in patients with relapsed or refractory multiple myeloma. Reports indicate that PIs have a unique toxicity profile that includes thrombocytopenia as a hematolo...
שמור ב:
| Principais autores: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publishing
2024-11-01
|
| סדרה: | Therapeutic Advances in Hematology |
| גישה מקוונת: | https://doi.org/10.1177/20406207241292517 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|